Download PDF
Semin intervent Radiol 2005; 22(2): 108-113
DOI: 10.1055/s-2005-871865
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Contrast-Induced Nephropathy: What We Know, What We Think We Know, and What We Don't Know

Brian Funaki1
  • 1Section of Vascular and Interventional Radiology, University of Chicago Hospitals, Chicago, Illinois
Further Information

Publication History

Publication Date:
28 June 2005 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Contrast-induced nephropathy is a common but poorly understood problem. A large body of literature devoted to the subject is replete with contradictions and conflicting reports. The purpose of this article is to summarize our current understanding of the problem by reviewing some of the best studies done to date. Recommendations based on the current literature are also provided.

KEYWORDS

Contrast - nephropathy - contrast-induced nephropathy - review - renal insufficiency - radiology

REFERENCES

  • 1 McCullough P A, Wolyn R, Rocher L L, Levin R N, O'Neill W W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.  Am J Med. 1997;  103 368-375
    CrossrefPubMedGoogle Scholar
  • 2 Rihal C S, Textor S C, Grill D E et al.. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.  Circulation. 2002;  105 2259-2264
    CrossrefPubMedGoogle Scholar
  • 3 Rudnick M R, Berns J S, Cohen R M, Goldfarb S. Contrast media-associated nephrotoxicity.  Semin Nephrol. 1997;  17 15-26
    PubMedGoogle Scholar
  • 4 Rudnick M R, Goldfarb S, Wexler L et al.. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.  Kidney Int. 1995;  47 254-261
    CrossrefPubMedGoogle Scholar
  • 5 Barrett B J, Carlisle E J. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media.  Radiology. 1993;  188 171-178
    PubMedGoogle Scholar
  • 6 Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents.  N Engl J Med. 1994;  331 1416-1420
    CrossrefPubMedGoogle Scholar
  • 7 Stone G W, McCullough P A, Tumlin J A et al.. CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.  JAMA. 2003;  290 2284-2291
    CrossrefPubMedGoogle Scholar
  • 8 Carraro M, Mancini W, Artero M et al.. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration.  Nephrol Dial Transplant. 1996;  11 444-448
    PubMedGoogle Scholar
  • 9 Mueller C, Buerkle G, Buettner H J et al.. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.  Arch Intern Med. 2002;  162 329-336
    PubMedGoogle Scholar
  • 10 Allaqaband S, Tumuluri R, Malik A M et al.. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.  Catheter Cardiovasc Interv. 2002;  57 279-283
    PubMedGoogle Scholar
  • 11 Spinosa D J, Matsumoto A H, Angle J F et al.. Gadolinium-based contrast and carbon dioxide angiography to evaluate renal transplants for vascular causes of renal insufficiency and accelerated hypertension.  J Vasc Interv Radiol. 1998;  9 909-916
    PubMedGoogle Scholar
  • 12 Spinosa D J, Matsumoto A H, Angle J F, Hagspiel K D, McGraw J K, Ayers C. Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment.  Radiology. 1999;  210 663-672
    PubMedGoogle Scholar
  • 13 Spinosa D J, Angle J F, Hagspiel K D, Kern J A, Hartwell G D, Matsumoto A H. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency.  J Vasc Interv Radiol. 2000;  11 35-43
    PubMedGoogle Scholar
  • 14 Ailawadi G, Stanley J C, Williams D M, Dimick J B, Henke P K, Upchurch Jr G R. Gadolinium as a nonnephrotoxic contrast agent for catheter-based arteriographic evaluation of renal arteries in patients with azotemia.  J Vasc Surg. 2003;  37 346-352
    CrossrefPubMedGoogle Scholar
  • 15 Sam II A D, Morasch M D, Collins J, Song G, Chen R, Pereles F S. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.  J Vasc Surg. 2003;  38 313-318
    CrossrefPubMedGoogle Scholar
  • 16 Nyman U, Elmstahl B, Leander P, Nilsson M, Golman K, Almen T. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?.  Radiology. 2002;  223 311-318 discussion 328-329
    PubMedGoogle Scholar
  • 17 Caridi J G, Stavropoulos S W, Hawkins Jr I F. CO2 digital subtraction angiography for renal artery angioplasty in high-risk patients.  AJR Am J Roentgenol. 1999;  173 1551-1556
    PubMedGoogle Scholar
  • 18 Kessel D O, Robertson I, Patel 5th J. et al . Carbon-dioxide-guided vascular interventions: technique and pitfalls.  Cardiovasc Intervent Radiol. 2002;  25 476-483
    CrossrefPubMedGoogle Scholar
  • 19 Cigarroa R G, Lange R A, Williams R H, Hillis L D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease.  Am J Med. 1989;  86 649-652
    PubMedGoogle Scholar
  • 20 Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency.  Nephrol Dial Transplant. 1998;  13 358-362
    PubMedGoogle Scholar
  • 21 Vogt B, Ferrari P, Schonholzer C et al.. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.  Am J Med. 2001;  111 692-698
    CrossrefPubMedGoogle Scholar
  • 22 Marenzi G, Marana I, Lauri G et al.. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.  N Engl J Med. 2003;  349 1333-1340
    CrossrefPubMedGoogle Scholar
  • 23 Merten G J, Burgess W P, Gray L V et al.. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;  291 2328-2334
    CrossrefPubMedGoogle Scholar
  • 24 Stevens M A, McCullough P A, Tobin K J et al.. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.  J Am Coll Cardiol. 1999;  33 403-411
    CrossrefPubMedGoogle Scholar
  • 25 Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.  N Engl J Med. 2000;  343 180-184
    CrossrefPubMedGoogle Scholar
  • 26 Baker C S, Wragg A, Kumar S, De Palma R, Baker L R, Knight C J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.  J Am Coll Cardiol. 2003;  41 2114-2118
    CrossrefPubMedGoogle Scholar
  • 27 Kay J, Chow W H, Chan T M et al.. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.  JAMA. 2003;  289 553-558
    CrossrefPubMedGoogle Scholar
  • 28 Briguori C, Manganelli F, Scarpato P et al.. Acetylcysteine and contrast agent-associated nephrotoxicity.  J Am Coll Cardiol. 2002;  40 298-303
    CrossrefPubMedGoogle Scholar
  • 29 Webb J G, Pate G E, Humphries K H et al.. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.  Am Heart J. 2004;  148 422-429
    CrossrefPubMedGoogle Scholar
  • 30 Oldemeyer J B, Biddle W P, Wurdeman R L, Mooss A N, Cichowski E, Hilleman D E. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.  Am Heart J. 2003;  146 E23
    PubMedGoogle Scholar
  • 31 Durham J D, Caputo C, Dokko J et al.. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography.  Kidney Int. 2002;  62 2202-2207
    CrossrefPubMedGoogle Scholar
  • 32 Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude F J, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis.  Lancet. 2003;  362 598-603
    CrossrefPubMedGoogle Scholar
  • 33 Nallamothu B K, Shojania K G, Saint S et al.. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.  Am J Med. 2004;  117 938-947
    CrossrefPubMedGoogle Scholar
  • 34 Kshirsagar A V, Poole C, Mottl A et al.. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.  J Am Soc Nephrol. 2004;  15 761-769
    CrossrefPubMedGoogle Scholar
  • 35 Aspelin P, Aubry P, Fransson S G, Strasser R, Willenbrock R, Berg K J. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators . Nephrotoxic effects in high-risk patients undergoing angiography.  N Engl J Med. 2003;  348 491-499
    CrossrefPubMedGoogle Scholar
  • 36 Chalmers N, Jackson R W. Comparison of iodixanol and iohexol in renal impairment.  Br J Radiol. 1999;  72 701-703
    PubMedGoogle Scholar
  • 37 Carraro M, Malalan F, Antonione R et al.. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial.  Eur Radiol. 1998;  8 144-147
    CrossrefPubMedGoogle Scholar

Brian FunakiM.D. 

Section of Vascular and Interventional Radiology, University of Chicago Hospitals

5840 S., Maryland Avenue, MC 2026

Chicago, IL 60637